Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRX Immuneering Corp

Pre-Mkt 12-23 04:07:53 EST

5.91

+0.26

+4.60%

High5.98	Low5.46	Vol1.47M
Open5.66	D1 Closing5.65	Amplitude9.09%
Mkt Cap381.61M	Tradable Cap321.57M	Total Shares64.57M
T/O8.64M	T/O Rate2.71%	Tradable Shares54.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":5.91,"timestamp":1766437200000,"preClose":5.65,"halted":0,"volume":1474781,"delay":0,"floatShares":54411779,"shares":64569967,"eps":-1.75688,"marketStatus":"Pre-Mkt","change":0.26,"latestTime":"12-23 04:07:53 EST","open":5.66,"high":5.975,"low":5.4615,"amount":8638802.541985,"amplitude":0.090885,"askPrice":8,"askSize":10,"bidPrice":2.44,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.75688,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766500200000},"marketStatusCode":1,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":5.91,"postHourTrading":{"tag":"盘后","latestPrice":6,"preClose":5.91,"latestTime":"19:48 EST","volume":237233,"amount":1402177.355,"timestamp":1766450917227},"volumeRatio":0.697801,"impliedVol":0.5979,"impliedVolPercentile":0.1228},"requestUrl":"/m/hq/s/IMRX","defaultTab":"news","newsList":[{"id":"2592943915","title":"BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943915","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943915?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:08","pubTimestamp":1766005722,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib TrialDec 17 (Reuters) - Immuneering Corp IMRX.O:IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4563","BK4139","BK4539"],"gpt_icon":0},{"id":"2592943674","title":"Immuneering: Expects to Share Topline Results From Trial in Mid-2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943674?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:05","pubTimestamp":1766005550,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18V:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4563","BK4139","BK4539"],"gpt_icon":0},{"id":"2592943671","title":"Immuneering Expects to Dose First Patient in Global Phase 3 Registrational Trial, Mapkeeper 301, in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943671?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:05","pubTimestamp":1766005550,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","IMRX","BK4563"],"gpt_icon":0},{"id":"2592943942","title":"Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943942","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943942?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:05","pubTimestamp":1766005500,"startTime":"0","endTime":"0","summary":"– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Ov","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3207312/0/en/Immuneering-Advances-Towards-Dosing-First-Patient-in-Phase-3-Atebimetinib-Trial-for-First-Line-Metastatic-Pancreatic-Cancer-Patients-Securing-Alignment-with-FDA-and-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081","BK4563","BK4139","IMRX","BK4539"],"gpt_icon":0},{"id":"2591847659","title":"Immuneering Corporation joins Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2591847659","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591847659?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:00","pubTimestamp":1765890025,"startTime":"0","endTime":"0","summary":"Immuneering Corporation will be added to the Nasdaq Biotechnology Index  effective prior to market open on December 22, 2025. The addition follows the annual evaluation of the NBI, which requires companies to meet eligibility criteria such as minimum market capitalization and trading volume.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire  on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL7tyQJ7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SG9999014039.USD","BK4585","SG9999014005.SGD","NDAQ","IMRX","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BKPKM429.USD","BK4112","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD","BK4563","IE00B3QW5Z07.USD","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","BK4588","LU2210150020.SGD"],"gpt_icon":0},{"id":"2586734614","title":"Immuneering Corporation to Present at Piper Sandler Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2586734614","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586734614?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:00","pubTimestamp":1764075614,"startTime":"0","endTime":"0","summary":"Immuneering Corporation will present at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 4, 2025. The company's management team, including CEO Ben Zeskind and other executives, will deliver a presentation from 11:10 to 11:30 a.m. ET. The event will be webcast live and later archived on Immuneering's Investor Relations website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL5F0y1c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","BK4563","LU0314104364.USD","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","BK4112","LU2210149790.SGD","BK4585","PIPR","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4139","BK4539","IMRX","BK4127"],"gpt_icon":0},{"id":"2585454342","title":"U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels","url":"https://stock-news.laohu8.com/highlight/detail?id=2585454342","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585454342?lang=en_us&edition=fundamental","pubTime":"2025-11-24 16:05","pubTimestamp":1763971553,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt HotelsNov 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nL4N3X00BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","EXAS","GPN","CPRT","FISV","RBA","VEEV","BK4535","RIGL","BDN","LU1923622291.USD","CVNA","CPAY","FLUT","IMRX","LSPD","LU0211331839.USD","LU0354030438.USD","CDXS","LU2449936058.SGD","LB","LU1861558580.USD","BK4007","VNO","LU0476273544.USD","LU1861559042.SGD","CF","BK4099","LU0588546209.SGD","ALHC","NAVN","PRKS","STLA","LU0306807586.USD","LU0321505439.SGD","LU2298321311.HKD","MOS","AZTA","BMY","BLTE","BJ","WEX","COGT","HSBA.UK","LU1917777945.USD","H","GAP","TSCO","BK4559"],"gpt_icon":1},{"id":"2585126986","title":"Immuneering Showcases Promising Phase 2 Pancreatic Cancer Data for Atebimetinib Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2585126986","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585126986?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:33","pubTimestamp":1763760826,"startTime":"0","endTime":"0","summary":"Immuneering Corporation has shared new data from its ongoing Phase 2a study evaluating atebimetinib in combination with modified gemcitabine and nab-paclitaxel  for first-line treatment of pancreatic cancer. The study reports a median progression-free survival  of 9.6 months for the atebimetinib + mGnP combination in a broad patient population. By comparison, benchmark mPFS values for standard regimens are reported as 5.5 months for GnP, 6.4 months for FOLFIRINOX, and 7.4 months for NALIRIFOX. At nine months, progression-free survival probability was 53% [31, 71] for patients receiving atebimetinib + mGnP. The median follow-up for overall survival was 9.0 months as of the August 26, 2025 data cutoff. No head-to-head clinical trials have been conducted, and differences exist between trial designs and subject characteristics. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLDgg1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4563","BK4539"],"gpt_icon":0},{"id":"2584840779","title":"Immuneering (IMRX) Gets a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2584840779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584840779?lang=en_us&edition=fundamental","pubTime":"2025-11-18 16:16","pubTimestamp":1763453811,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Immuneering. The company’s shares closed yester...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immuneering-imrx-gets-a-buy-from-mizuho-securities-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immuneering-imrx-gets-a-buy-from-mizuho-securities-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","BK4207","BK4139","BK4563","BK4539","IMRX"],"gpt_icon":0},{"id":"2583493945","title":"Immuneering Corp. Shines in Positive Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2583493945","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583493945?lang=en_us&edition=fundamental","pubTime":"2025-11-14 08:36","pubTimestamp":1763080571,"startTime":"0","endTime":"0","summary":"Immuneering Corp. Class A (($IMRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Immuneering Corp. Class A’s recent ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immuneering-corp-shines-in-positive-earnings-call?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immuneering-corp-shines-in-positive-earnings-call?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX"],"gpt_icon":0},{"id":"2583515940","title":"BUZZ-U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APA","url":"https://stock-news.laohu8.com/highlight/detail?id=2583515940","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583515940?lang=en_us&edition=fundamental","pubTime":"2025-11-14 03:09","pubTimestamp":1763060958,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APAEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL6N3WP0NC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTRI","HAL","NEM","SPB","SSYS","SG","CDE","PSFE","BR","ANNX","IONS","HZO","ALB","CLBT","AMAT","IMRX","IE0009355771.USD","MRSN","XNET","LU0234572021.USD","ARDT","MRK","SBH","SCVL","LU2458330243.SGD","KURA","FLY","DDS","THAR","VZ","BTDR","APA","DASH","HL","SLB","EPC","MGRX","CVX","SEE","BWEN","CTEV"],"gpt_icon":1},{"id":"2583698594","title":"BUZZ-Immuneering rises after smaller-than-expected Q3 loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2583698594","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583698594?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:27","pubTimestamp":1763047666,"startTime":"0","endTime":"0","summary":"BUZZ-Immuneering rises after smaller-than-expected Q3 loss** Shares of therapy developer Immuneering Corp.IMRX.O rise 7% to $7.08 ** Company posts Q3 net loss of 38 cents per share compared to analysts' estimated loss of 39 cents per share ** Cash, and cash equivalents as of September 30 were $227.6 million, compared with $36.1 million as of December 31, 2024** Including session's moves, stock has more than tripled YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL4N3WP19G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4563","BK4539"],"gpt_icon":0},{"id":"2583759511","title":"Immuneering Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583759511","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583759511?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:01","pubTimestamp":1763042460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 09:01 ET (14:01 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2583585138","title":"Immuneering reports Q3 EPS (38c), consensus (39c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583585138","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583585138?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:30","pubTimestamp":1762983052,"startTime":"0","endTime":"0","summary":"“The third quarter was truly transformational for Immuneering (IMRX). We announced extraordinary overall survival data from our ongoing Phase 2a tr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-reports-q3-eps-38c-consensus-39c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-reports-q3-eps-38c-consensus-39c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX"],"gpt_icon":0},{"id":"2583856945","title":"Immuneering expects cash to fund operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2583856945","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583856945?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:30","pubTimestamp":1762983041,"startTime":"0","endTime":"0","summary":"Based on cash, and cash equivalents as of September 30, 2025, and current operating plans, the Company expects its cash runway to be sufficient to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-expects-cash-to-fund-operations-into-2029-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-expects-cash-to-fund-operations-into-2029-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX","BK4139","BK4563","BK4539"],"gpt_icon":0},{"id":"2583979583","title":"Immuneering reports smaller-than-expected Q3 net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2583979583","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583979583?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:24","pubTimestamp":1762982675,"startTime":"0","endTime":"0","summary":"Immuneering reports smaller-than-expected Q3 net lossOverviewImmuneering Q3 net loss of $15 mln beats analyst expectationsCompany raised $225 mln, extending cash runway into 2029Reported 86% overall s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO13K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IMRX","BK4139","BK4563"],"gpt_icon":0},{"id":"2583588434","title":"Immuneering Granted U.S. Patent for Atebimetinib, Providing Exclusivity Into 2042","url":"https://stock-news.laohu8.com/highlight/detail?id=2583588434","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583588434?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:07","pubTimestamp":1762981631,"startTime":"0","endTime":"0","summary":"Immuneering Corporation announced that it has been granted a U.S. composition of matter patent for atebimetinib, which is expected to provide exclusivity into 2042.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL9HWnyM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4112","BK4563","IE00B3QW5Z07.USD","LU0314104364.USD","BK4139","BK4539","IE00B64PRP62.GBP","BK4588","IMRX","IE00BGHQF748.EUR","LU2210149790.SGD"],"gpt_icon":0},{"id":"2583588581","title":"Immuneering Q3 EPS $(0.38) Beats $(0.39) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583588581","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583588581?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:06","pubTimestamp":1762981617,"startTime":"0","endTime":"0","summary":"Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.39) by 3.06 percent. This is a 22.45 percent increase over losses of $(0.49) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48818866/immuneering-q3-eps-0-38-beats-0-39-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immuneering Q3 EPS $(0.38) Beats $(0.39) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"gpt_icon":0},{"id":"2582327400","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2582327400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582327400?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:00","pubTimestamp":1762945200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CI&T Inc. Class A                               3Q       .10        AMC. ·Digi Intl Inc.                                  4Q       .51    4:00 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFYA","RSKD","CPRT","PYPD","MGX","ARDT","ARX","ATAT","BLDP","ALUR","CREX","ATXS","BEEM","CURI","ARCO","CRMD","AVBP","CRMT","IBTA","LUNG","AFCG","CINT","CSCO","CABA","CELC","AIRG","ALVO","AUTL","IMRX","ABSI","ASND","ANNX","ACXP","AEBI","GUTS","ALC","CAAP","CCAP","CLBT","ALMS","AMAT","TWFG","ABOS","AEMD","BABA","AYTU","AKRO","ABEO","ALH"],"gpt_icon":1},{"id":"2581761119","title":"Immuneering Corporation to Release Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581761119","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581761119?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:05","pubTimestamp":1762290321,"startTime":"0","endTime":"0","summary":"Immuneering Corporation will report third quarter 2025 financial results on Wednesday, November 12, 2025, after the close of market. Trial investigators will also provide new clinical case studies. Results will be released in the \"Investors\" section of the Company's website. A conference call and webcast will be held the same day at 4:30 pm ET with trial investigators in attendance. The webcast can be accessed via the Events page.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL1RJgtQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","IMRX","BK4585","LU2210150020.SGD","BK4563","IE00BGHQF748.EUR","BK4139","BK4539","NDAQ","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":0.0225},{"period":"1month","weight":-0.1904},{"period":"3month","weight":-0.312},{"period":"6month","weight":0.957},{"period":"1year","weight":1.955},{"period":"ytd","weight":1.6864}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.209299},{"month":2,"riseRate":0.5,"avgChangeRate":-0.044801},{"month":3,"riseRate":0.25,"avgChangeRate":0.059789},{"month":4,"riseRate":0.25,"avgChangeRate":-0.2067},{"month":5,"riseRate":0.25,"avgChangeRate":0.005771},{"month":6,"riseRate":0.75,"avgChangeRate":0.3519},{"month":7,"riseRate":0.75,"avgChangeRate":0.027683},{"month":8,"riseRate":0.4,"avgChangeRate":0.157517},{"month":9,"riseRate":0.8,"avgChangeRate":0.592866},{"month":10,"riseRate":0.2,"avgChangeRate":-0.073665},{"month":11,"riseRate":0.4,"avgChangeRate":-0.104912},{"month":12,"riseRate":0.4,"avgChangeRate":-0.118712}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}